Plus, news about Longevity Biomedical, Sensorion, Teva and Bristol Myers Squibb: Context Therapeutics buys a T cell engager: The biotech will pay $15 million upfront and up to $118.5 million in ...

Black Diamond Therapeutics’ stock price $BDTX jumped more than 15% premarket Monday morning after the company reported its ...

For AI-focused startups seeking out pharma deals, they have to go through people like Greg Meyers, the chief digital and ...

Sanofi has stayed out of the obesity drug development bonanza, taking a wait-and-see approach while keeping an eye on ...

Australian radiopharma company Telix Pharmaceuticals is acquiring radioisotope manufacturer RLS Radiopharmacies in another ...

Ideaya Biosciences has set the stage on what a Phase 3 trial would look like for its rare eye cancer drug darovasertib, after ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate failed a key survival endpoint in a late-phase breast ...

As an­ti­body–drug con­ju­gates (AD­Cs) and im­mune check­point in­hibitors con­tin­ue to grab a lot of at­ten­tion as trans­for­ma­tive can­cer ther­a­pies, they would ap­pear to leave lit­tle room ...

The former head of vaccine R&D at GSK has pulled together $100 million for a London-based biotech working on respiratory ...

Another biotech startup revealed plans Friday evening for an initial public offering, making it the sixth startup to list new ...

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every ...

A small ge­net­ic test­ing start­up backed by Pe­ter Thiel’s Founders Fund and Red­dit co-founder Alex­is Ohan­ian’s 776 Fund ...